Trial Profile
Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With IGF-1
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Mecasermin (Primary)
- Indications Rett syndrome
- Focus Adverse reactions; Pharmacokinetics
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Mar 2012 Planned number of patients changed from 40 to 42 as reported by ClinicalTrials.gov.
- 09 Dec 2010 New trial record